ITMCTR2100004325招募中2 期
A multi-center, randomized, double-blind, dose exploration, placebo parallel controlled phase II clinical trial to evaluate the efficacy and safety of Yuping Tongqiao Tablets in the treatment of persistent allergic rhinitis (deficiency of lung and spleen)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •(1) Meet the diagnostic criteria for persistent allergic rhinitis;
- •(2) At least 2 of the nasal symptoms sneezing, runny nose, nasal congestion, nasal itching are moderate or severe (score >= 2 points);
- •(3) Comply with TCM syndrome differentiation of lung and spleen deficiency syndrome;
- •(4) Age from 18 to 65 years old (including 18 and 65 years old), male or female;
- •(5) Volunteer to participate in this clinical trial and sign a written informed consent.
排除标准
- •(1) Subjects with severe nasal septum deviation, sinusitis, nasal polyps, hypertrophic rhinitis and other organic nasal diseases;
- •(2) Subjects with various types of asthma such as bronchial asthma and cough variant asthma;
- •(3) Received allergen immunotherapy before enrollment or received nasal surgery within 6 months before enrollment;
- •(4) Received intranasal or systemic corticosteroids, leukotriene regulators, and immunotherapy within 30 days before enrollment; received antihistamines, mast cell membrane stabilizers within 14 days; received anticholinergics, Chinese medicine within 7 days and other non-drug treatments that have therapeutic effects on AR, such as acupuncture and acupoint application; received decongestants within 3 days; or plan to receive the above-mentioned drugs or treatments during the study due to comorbid diseases; (Excluding emergency devices used in this study);
- •(5) Scr is greater than the upper limit of the reference value or ALT, AST > 1.5 times the upper limit of the reference value;
- •(6) Subjects who have any of the following documented conditions: Severe diseases) of major organs or systems such as the heart, brain, liver, kidney, respiratory system, circulatory system, endocrine system, immune system, hematopoietic system, etc. (such as acute myocardial infarction, malignant tumors, tuberculosis, severe hypertension Diabetic ketoacidosis and other diabetes comorbidities, HIV and other immunodeficiency diseases, rheumatoid arthritis, systemic lupus erythematosus and other autoimmune diseases, leukemia, etc.);
- •(7) Pregnant or lactating women, or have a childbirth plan in the next six months, or are unwilling to take effective contraceptive measures during the trial period or within six months after stopping the drug;
- •(8) A history of allergy to components of study medication;
- •(9) Large area trauma to the nasal cavity, or severe sodium chloride allergy or sodium chloride metabolism disorder;
- •(10) A long-term history of alcohol and drug abuse;
- •(11) There is an intellectual or mental disorder;
- •(12) Participated in clinical trials of other drugs or medical devices in the past 3 months;
- •(13) The investigator believes that the subject is not suitable to participate in this clinical trial. in the opinion of the investigator, the subject's compliance with the protocol (including visit plan, diary card or questionnaire) may be affected by the subject's physical, cultural level or frequent changes in the work environment.
研究者
相似试验
已完成
2 期
A multi-center, randomized, double-blind, dose-parallel, placebo-controlled phase II clinical trial to evaluate the effectiveness and safety of Ganmao Shuangjie Granules in the treatment of influenza (external cold, internal heat syndrome)influenza (external cold, internal heat syndromeITMCTR2100005067Beijing Hospital of Traditional Chinese Medicine
未知
3 期
A short treatment study of aripiprazole in pediatric patients with schizophreniaSchizophreniaJPRN-jRCT2080221112Otsuka Pharmaceutical Co., Ltd.99
进行中（未招募）
不适用
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1 or 4MedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-008258-21-ITF. Hoffmann - La Roche Ltd - Pharmaceutical Division, PDR400
进行中（未招募）
1 期
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.EUCTR2008-008258-21-GBF. Hoffmann-La Roche Ltd400
进行中（未招募）
不适用
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.Chronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-008258-21-DEF. Hoffmann-La Roche Ltd400